What's new? Log in Free sign up

Ascendis Pharma A/S (ASND)

Company Profile

Company profile

Ticker

ASND

Exchange

Website

ascendispharma.com

CEO

Mr. Jan Moller Mikkelsen

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

Insynergy Products, Inc

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

ASND stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$197.67

Low target

$168.00

High target

$225.00

Cantor Fitzgerald

Latest filings (excl ownership)

View all

Registration of securities for employees

Annual report (foreign)

Current report (foreign)

Ascendis Pharma Reports Fourth Quarter and Full Year 2024

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart ASND financial data

Quarter (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q4 2024

ASND institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	213	217	-1.8%
Opened positions	36	43	-16.3%
Closed positions	40	26	+53.8%
Increased positions	83	78	+6.4%
Reduced positions	65	66	-1.5%

13F shares	Current	Prev Q	Change
Total value	7.75 tn	8.38 tn	-7.5%
Total shares	63.76 mm	62.53 mm	+2.0%
Total puts	212.50 k	373.80 k	-43.2%
Total calls	78.20 k	248.20 k	-68.5%
Total put/call ratio	2.7	1.5	+80.4%

Largest owners	Shares	Value	Change
Ra Capital Management	10.11 mm	$1.39 tn	+4.1%
Westfield Capital Management	5.53 mm	$761.07 bn	+7.7%
Avoro Capital Advisors	5.10 mm	$702.54 bn	+2.3%
FMR	4.73 mm	$650.99 bn	-3.7%
Artisan Partners Limited Partnership	4.45 mm	$612.69 bn	+0.9%
JHG Janus Henderson	4.38 mm	$602.91 bn	+4.6%
Capital International Investors	2.86 mm	$394.18 bn	+35.7%
T. Rowe Price Investment Management	2.73 mm	$375.23 mm	+54.4%
T. Rowe Price	2.28 mm	$314.33 mm	+7.6%
Massachusetts Financial Services	1.87 mm	$257.11 bn	+0.0%

Largest transactions	Shares	Bought/sold	Change
T. Rowe Price Investment Management	2.73 mm	+960.50 k	+54.4%
Capital International Investors	2.86 mm	+753.86 k	+35.7%
Spyglass Capital Management	0.00	-652.84 k	EXIT
Wellington Management	704.18 k	-557.30 k	-44.2%
MS Morgan Stanley	825.76 k	+513.27 k	+164.3%
TimesSquare Capital Management	0.00	-500.92 k	EXIT
Adage Capital Partners GP, L.L.C.	0.00	-486.96 k	EXIT
Brown Advisory	36.29 k	-431.37 k	-92.2%
Ra Capital Management	10.11 mm	+402.32 k	+4.1%
Westfield Capital Management	5.53 mm	+394.47 k	+7.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $200

Cantor Fitzgerald analyst Li Watsek maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $170 to $200.

Why Is BioMarin Stock Trading Higher On Thursday?

BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results.

Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today

Evercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $260

Press releases

From Benzinga Pro

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on

FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA

YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1First-in-class novel PTH replacement therapyAustralia

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

– Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million – Following pre-NDA meeting with FDA, on track to submit TransCon™ CNP NDA

Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.